Spruce Biosciences Stock Current Asset
| SPRB Stock | USD 0.48 0.01 2.04% |
Spruce Biosciences fundamentals help investors to digest information that contributes to Spruce Biosciences' financial success or failures. It also enables traders to predict the movement of Spruce Stock. The fundamental analysis module provides a way to measure Spruce Biosciences' intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Spruce Biosciences stock.
As of November 24, 2024, Non Current Assets Total is expected to decline to about 1.7 M. In addition to that, Other Current Assets is expected to decline to about 3.2 M. Spruce | Current Asset |
Spruce Biosciences Company Current Asset Analysis
Spruce Biosciences' Current Asset is all of the company's assets that can be used to pay off current liabilities within the current fiscal period or over the next 12 months. Current Asset includes cash or cash equivalents, accounts receivable, short-term investments, and the portion of prepaid liabilities which will be paid within the next 12 months. Because these assets are easily turned into cash, they are sometimes referred to as liquid assets.
Spruce Current Asset Historical Pattern
Today, most investors in Spruce Biosciences Stock are looking for potential investment opportunities by analyzing not only static indicators but also various Spruce Biosciences' growth ratios. Consistent increases or drops in fundamental ratios usually indicate a possible pattern that can be successfully translated into profits. However, when comparing two companies, knowing each company's current asset growth rates may not be enough to decide which company is a better investment. That's why investors frequently use a static breakdown of Spruce Biosciences current asset as a starting point in their analysis.
Spruce Biosciences Current Asset |
| Timeline |
Current Asset is important to company's creditors and private equity firms as they will often be interested in how much that company has in current assets since these assets can be easily liquidated in case the company goes bankrupt. However, it is usually not enough to know if a company is in good shape just based on current asset alone; the amount of current liabilities should always be considered.
| Competition |
Spruce Total Assets
Total Assets |
|
In accordance with the recently published financial statements, Spruce Biosciences has a Current Asset of 0.0. This is 100.0% lower than that of the Biotechnology sector and 100.0% lower than that of the Health Care industry. The current asset for all United States stocks is 100.0% higher than that of the company.
Did you try this?
Run Risk-Return Analysis Now
Risk-Return AnalysisView associations between returns expected from investment and the risk you assume |
| All Next | Launch Module |
Spruce Fundamentals
| Return On Equity | -0.58 | ||||
| Return On Asset | -0.3 | ||||
| Operating Margin | (15.63) % | ||||
| Current Valuation | (36.86 M) | ||||
| Shares Outstanding | 41.3 M | ||||
| Shares Owned By Insiders | 7.72 % | ||||
| Shares Owned By Institutions | 41.43 % | ||||
| Number Of Shares Shorted | 232.77 K | ||||
| Price To Book | 0.39 X | ||||
| Price To Sales | 2.81 X | ||||
| Revenue | 10.09 M | ||||
| EBITDA | (47.37 M) | ||||
| Net Income | (47.92 M) | ||||
| Cash And Equivalents | 93.3 M | ||||
| Cash Per Share | 3.96 X | ||||
| Total Debt | 4.61 M | ||||
| Debt To Equity | 0.07 % | ||||
| Current Ratio | 9.55 X | ||||
| Book Value Per Share | 1.25 X | ||||
| Cash Flow From Operations | (33.27 M) | ||||
| Short Ratio | 0.43 X | ||||
| Earnings Per Share | (0.95) X | ||||
| Target Price | 2.33 | ||||
| Number Of Employees | 29 | ||||
| Beta | 2.37 | ||||
| Market Capitalization | 19.96 M | ||||
| Total Asset | 103.95 M | ||||
| Retained Earnings | (197.23 M) | ||||
| Working Capital | 77.72 M | ||||
| Net Asset | 103.95 M |
About Spruce Biosciences Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Spruce Biosciences's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Spruce Biosciences using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Spruce Biosciences based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.When determining whether Spruce Biosciences offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Spruce Biosciences' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Spruce Biosciences Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Spruce Biosciences Stock:Check out Spruce Biosciences Piotroski F Score and Spruce Biosciences Altman Z Score analysis. For information on how to trade Spruce Stock refer to our How to Trade Spruce Stock guide.You can also try the Latest Portfolios module to quick portfolio dashboard that showcases your latest portfolios.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Spruce Biosciences. If investors know Spruce will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Spruce Biosciences listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (0.95) | Revenue Per Share 0.173 | Quarterly Revenue Growth (0.80) | Return On Assets (0.30) | Return On Equity (0.58) |
The market value of Spruce Biosciences is measured differently than its book value, which is the value of Spruce that is recorded on the company's balance sheet. Investors also form their own opinion of Spruce Biosciences' value that differs from its market value or its book value, called intrinsic value, which is Spruce Biosciences' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Spruce Biosciences' market value can be influenced by many factors that don't directly affect Spruce Biosciences' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Spruce Biosciences' value and its price as these two are different measures arrived at by different means. Investors typically determine if Spruce Biosciences is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Spruce Biosciences' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.